Negotiable
The date of payment from buyers deliver within days
Shanghai
Long-term effective
2019-01-20 04:23
478
saimai2018(Mr.)
Shanghai
Room 156, 133# Dongzheng Road, Pudong Disrict, Shanghai, China
http://www.therapeuticmab.com/ http://www.xr119.com/com/saimai2018/
This product is the biosimilar of Avelumab (1537032-82-8), which is a programmed death ligand-1 (PD-L1) blocking antibody. The biosimilar is a human IgG1 lambda monoclonal antibody that has a molecular weight of approximately 147 kDa, which is produced by recombinant DNA technology in Chinese Hamster Ovary cell expression system and is purified by a process that includes specific viral inactivation and removal steps.
Features and Advantages:
Name |
Biosimilar of Avelumab |
CAS NO. |
1537032-82-8 |
Type |
Whole antibody |
Source |
Human |
Target |
PD-L1 |
Clone |
Monoclone |
Molecular Weight |
147 kDa |
Antibody Form |
Purified immunoglobulin |
Physical Form |
Solution |
Place of Origin |
China (Mainland) |
Storage |
Sealed and stored at -70±15℃, away from light |
Specifications:
The biosimilar of Avelumab is supplied at a concentration of 20 mg/mL in the same buffer system with original drug (BAVENCIO) as a sterile, clear and colorless, preservative-free solution. In addition, our company also provides customized services according to customers' needs.
Annual production of the biosimilar of Avelumab stock is 80~150kgs, in addition, our company also provides small packaging (1g) for customers to evaluate product quality, for more information please contact us.
Applications:
Avelumab, the trade name BAVENCIO, is a pharmaceutical drug for use in immunotherapy, for the treatment of non-small-cell lung carcinoma (NSCLC), gastric cancer, Merkel-cell carcinoma.
The formulation and filling of the biosimilar of Avelumab is carried out under cGMP conditions as defined by the worldwide regulatory agencies including US FDA, EMA, CFDA. T Our products are only used in scientific research and are strictly prohibited for clinical and commercial use before approve by FDA.
http://www.therapeuticmab.com/